Veru V2011801
To assess the safety and tolerability of sabizabulin monotherapy, and Trodelvy/sabizabulin combination therapy
Trial overview
Topic
Veru V2011801
Description
Phase 2 Clinical Efficacy and Safety Study of Sabizabulin (VERU-111) Monotherapy and Sacituzumab Govitecan-hziy/Sabizabulin Combination Therapy for the Treatment of Metastatic Triple Negative Breast Cancer